Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.
about
Targeted therapies in development for non-small cell lung cancerCIViC databaseThe Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung CancerBRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Beyond histology: translating tumor genotypes into clinically effective targeted therapies.Increased BRAF copy number in lung adenocarcinomaClinical detection and categorization of uncommon and concomitant mutations involving BRAF.Personalizing therapy in advanced non-small cell lung cancerClinical Challenges to Current Molecularly Targeted Therapies in Lung CancerMutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapiesClinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?Emerging protein kinase inhibitors for non-small cell lung cancer.Republished: lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer.Emerging targeted therapies in non-small cell lung cancer.[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14
P2860
Q27022852-8EEAE2B7-1435-434B-9FE2-CEB6E59EABE1Q27612411-F796115A-3C27-4248-8456-9BA8B277A5DDQ28067196-1D090149-9969-4AD7-AF6C-A49362CD93F3Q30458424-D36CA6DD-8703-4FC9-85E8-EEC290400FB0Q33560928-8A1F797D-2F9A-41F6-B516-B072C4EAE296Q34993692-8E307575-E583-48A8-AF1F-BDCB4F8B957CQ35820044-4741119C-6D71-444D-95F2-118BF815337BQ36811453-81740449-37C3-4E9B-A93D-F3B0E6531335Q36972377-1887D0D8-66B6-4D95-A358-B5B9769D6A47Q37051546-EF2AB064-B8FE-4A5F-8C1E-CD68CC4BFF68Q37058831-13FACF80-7519-4DCB-A7A9-BF3A821B9916Q37146673-5B47A754-5335-4F73-AE7C-AE26ABCAD68AQ37220424-186A8B7C-F189-4589-B351-52CC7A25E859Q37451255-BE436679-E596-4D67-A627-A5DF1BE84320Q37599935-D6E83BFF-7CB0-4AE7-BC35-11BD2F4C10FFQ37632230-BB4C2C56-2A5D-4A71-B11F-ACD60DA4B637Q38105532-967CEEE5-9750-4D69-8B4D-628227D7C7DEQ38172608-BDEC50B5-6BA2-4E47-9DF3-FD02589DAF38Q38197071-7C2691F3-2501-4FBC-BDCA-D4E84ECE5529Q38213830-20E02166-81ED-4D3F-98D6-9A7BCA41C00FQ38245669-56089D36-6D31-4C65-ACF2-896615AB7BAFQ38653045-7D6C8ECA-DD6A-444E-A5B6-7A718360405BQ40530427-91309535-D5CE-4F97-86F3-9EECC743EFE0Q41952724-C361409A-1DA7-4FD0-9FB4-D233B36B14A2Q52312436-645D44A0-D0C5-4F80-833A-DDD0F6673F3FQ59135417-91178BE9-D0EF-49E0-9D1C-C81C4B1582AB
P2860
Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Molecular characterization of ...... nt non-small-cell lung cancer.
@ast
Molecular characterization of ...... nt non-small-cell lung cancer.
@en
Molecular characterization of ...... nt non-small-cell lung cancer.
@nl
type
label
Molecular characterization of ...... nt non-small-cell lung cancer.
@ast
Molecular characterization of ...... nt non-small-cell lung cancer.
@en
Molecular characterization of ...... nt non-small-cell lung cancer.
@nl
altLabel
Molecular Characterization of ...... ant Non–Small-Cell Lung Cancer
@en
prefLabel
Molecular characterization of ...... nt non-small-cell lung cancer.
@ast
Molecular characterization of ...... nt non-small-cell lung cancer.
@en
Molecular characterization of ...... nt non-small-cell lung cancer.
@nl
P2093
P2860
P3181
P1476
Molecular characterization of ...... nt non-small-cell lung cancer.
@en
P2093
Charles M Rudin
Kelvin Hong
Michael Streit
P2860
P3181
P356
10.1097/JTO.0B013E31828BB1B3
P577
2013-05-01T00:00:00Z